Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

586 articles

Showing 1–7 of 7 articles · Keyword: nanomedicine Clear keyword

International journal of nanomedicine2026ReviewDrug Delivery

1. Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design

Bu F, Cao Y, Chen F, Wen Y, Xiong L

Reperfusion therapy has transformed acute ischemic stroke care, yet large-vessel recanalization does not ensure capillary reperfusion, preservation of the blood-brain barrier and neurovascular unit (BBB/NVU), or durable neurological recovery. Nanomedicine is still commonly judged by BBB crossing or…

Read the article
Expert review of anti-infective therapy2026ReviewNon-viral Gene DeliveryDrug Delivery

2. Engineering smart liposomes to combat antimicrobial resistance: from mechanistic design to clinical translation

Gawale K, Karawadiya A, Katawale S, Sawarkar S, Omri A

Antimicrobial resistance (AMR) represents a critical global health threat, surpassing the pace of discovery and clinical development of new antimicrobial agents. Therefore, innovative therapeutic strategies are urgently needed to enhance antibiotic efficacy, overcome multidrug-resistant infections, and limit…

Read the article
The Journal of pharmacy and pharmacology2026ReviewDrug Delivery

3. Bioengineered multifunctional nanomedicine for cancer theranostics: integrating targeted drug delivery, molecular imaging, and precision medicine

Dubey S, Prakash S, Deshwal Rk, Dwivedi M

Cancer remains a major global health challenge despite significant advances in diagnosis and treatment. Conventional therapies, including chemotherapy, radiotherapy, and surgery, are frequently constrained by non-specific drug distribution, systemic toxicity, multidrug resistance (MDR), and limitations in early tumor…

Read the article
Cancers2026ReviewNon-viral Gene DeliveryDrug Delivery

4. Drug Delivery Systems for Breast Cancer Treatment: From Design Principles to Clinical Translation

Sescu Va, Condriuc Ips, Spridon Lg, Cadinoiu An, Miron L, Atanase Li, Et Al.

Breast cancer is the most frequently diagnosed malignancy worldwide and remains a major cause of cancer-related mortality among women. Despite advances in screening, molecular classification, and systemic therapies, treatment of advanced and metastatic disease remains challenging because of tumor heterogeneity…

Read the article
ACS Nano2021ReviewDrug Delivery

5. In Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design

Paula M. Cevaal, Abdalla Ali, Ewa Czuba-Wojnilowicz, Jori Symons, Sharon R. Lewin, Christina Cortez-Jugo, Frank Caruso

T cells are attractive targets for immunotherapy, cancer, HIV, autoimmunity, and inflammation, but nanoparticle delivery to T cells remains a major technological challenge due to their nonphagocytic nature and multiple physiological barriers. There is a need for rational design principles for in vivo T cell-targeting…

Read the article
Chemical Society Reviews2017ReviewNon-viral Gene Delivery

6. Cellular Uptake of Nanoparticles: Journey Inside the Cell

Shahed Behzadi, Vahid Serpooshan, Wei Tao, Majd A. Hamaly, Mahmoud Y. Alkawareek, Erik C. Dreaden, Dennis Brown, Alaaldin M. Alkilany, Omid C. Farokhzad, Morteza Mahmoudi

Nanoparticles (NPs) are increasingly used in consumer goods, electronics, and pharmaceuticals, but their beneficial and/or deleterious effects ultimately arise from interactions at the cellular and subcellular level. While many NPs require safe entry into cells for therapeutic efficacy, efficient and controlled…

Read the article
Pharmaceutical Research2011ReviewNon-viral Gene Delivery

7. Cancer Immunotherapy and Nanomedicine

Wei-Yun Sheng, Leaf Huang

The immune system can recognise and kill pre-cancer and cancer cells, but surviving tumour cells learn to escape immune surveillance after immunoselection. Cancer immunotherapy aims to overcome these escape mechanisms. Nanomedicine offers tools—nanodiagnostics and nanobiopharmaceuticals—to deliver antigens…

Read the article
Articles | Brilliant Blue Biosciences